Compare Novartis with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs UNICHEM LAB - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS UNICHEM LAB NOVARTIS/
UNICHEM LAB
 
P/E (TTM) x 471.5 57.7 817.9% View Chart
P/BV x 27.4 0.6 4,414.3% View Chart
Dividend Yield % 1.7 2.2 74.8%  

Financials

 NOVARTIS   UNICHEM LAB
EQUITY SHARE DATA
    NOVARTIS
Mar-18
UNICHEM LAB
Mar-19
NOVARTIS/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs758292 259.6%   
Low Rs579182 318.1%   
Sales per share (Unadj.) Rs228.4167.7 136.2%  
Earnings per share (Unadj.) Rs31.7-3.6 -874.1%  
Cash flow per share (Unadj.) Rs32.85.9 551.4%  
Dividends per share (Unadj.) Rs10.004.00 250.0%  
Dividend yield (eoy) %1.51.7 88.6%  
Book value per share (Unadj.) Rs297.1372.3 79.8%  
Shares outstanding (eoy) m24.6970.38 35.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.91.4 207.1%   
Avg P/E ratio x21.1-65.3 -32.3%  
P/CF ratio (eoy) x20.439.9 51.2%  
Price / Book Value ratio x2.20.6 353.4%  
Dividend payout %31.5-110.2 -28.6%   
Avg Mkt Cap Rs m16,50516,680 99.0%   
No. of employees `0000.72.6 25.7%   
Total wages/salary Rs m1,4452,393 60.4%   
Avg. sales/employee Rs Th8,441.34,535.2 186.1%   
Avg. wages/employee Rs Th2,163.6919.8 235.2%   
Avg. net profit/employee Rs Th1,173.1-98.2 -1,194.5%   
INCOME DATA
Net Sales Rs m5,63911,801 47.8%  
Other income Rs m1,718984 174.6%   
Total revenues Rs m7,35712,785 57.5%   
Gross profit Rs m-63-835 7.5%  
Depreciation Rs m25674 3.8%   
Interest Rs m5575 73.5%   
Profit before tax Rs m1,575-600 -262.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792-343 -230.5%   
Profit after tax Rs m784-256 -306.7%  
Gross profit margin %-1.1-7.1 15.7%  
Effective tax rate %50.357.3 87.7%   
Net profit margin %13.9-2.2 -641.8%  
BALANCE SHEET DATA
Current assets Rs m9,52220,384 46.7%   
Current liabilities Rs m3,2965,029 65.5%   
Net working cap to sales %110.4130.1 84.8%  
Current ratio x2.94.1 71.3%  
Inventory Days Days37105 35.0%  
Debtors Days Days28135 21.1%  
Net fixed assets Rs m469,023 0.5%   
Share capital Rs m123141 87.6%   
"Free" reserves Rs m7,21326,058 27.7%   
Net worth Rs m7,33626,199 28.0%   
Long term debt Rs m00-   
Total assets Rs m11,10531,496 35.3%  
Interest coverage x29.5-7.0 -422.7%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.4 135.5%   
Return on assets %7.6-0.6 -1,319.4%  
Return on equity %10.7-1.0 -1,095.1%  
Return on capital %22.2-2.0 -1,111.6%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m618,188 0.7%   
Fx outflow Rs m3,630596 609.1%   
Net fx Rs m-3,5707,592 -47.0%   
CASH FLOW
From Operations Rs m1,610-3,278 -49.1%  
From Investments Rs m687-2,860 -24.0%  
From Financial Activity Rs m-2,677-24 11,059.9%  
Net Cashflow Rs m-380-4,690 8.1%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 15.1 13.2%  
FIIs % 1.6 3.0 53.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 31.7 67.8%  
Shareholders   41,647 20,176 206.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   SANOFI INDIA  ASTRAZENECA PHARMA  STRIDES PHARMA SCIENCE  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 292 Points Higher; Automobile and Metal Stocks Witness Buying(Closing)

After opening the day marginally higher, Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Oct 15, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - NATCO PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS